Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;40(4):e70048.
doi: 10.1002/jca.70048.

Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services

Aaron J Wyble  1 , V Rakesh Sethapati  1 , Steven R Post  1 , Haley McAloon  1 , Nancy Green  1 , Mayumi Nakagawa  1 , Michele Cottler-Fox  1 , Gina Drobena  1
Affiliations

Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services

Aaron J Wyble et al. J Clin Apher. 2025 Aug.

Abstract

In order to reflect patient needs given new treatment options for hematopoietic malignancies, autologous hematopoietic progenitor cell (HPC) collection goals were changed to 10 or 15 × 106 CD34+/kg (previously 20 × 106 CD34+/kg) for myeloma patients and to 5 × 106 CD34+/kg (previously 10 × 106 CD34+/kg) for lymphoma patients in March 2023. The minimum number of large volume leukapheresis (LVL) procedures required decreased from two to one. We analyzed the impact of these changes on apheresis and cell therapy laboratory (CTL) services. Data from the post-implementation period of April through December in 2023 were compared to those from the same 9-month periods in 2022 and 2021 as controls. The number of patients undergoing autologous HPC collection per month were examined. The numbers of LVL procedures, numbers of cryopreserved bags, and apheresis and CTL staffing hours and costs were determined retrospectively on a per patient and monthly basis. One-way ANOVA with Tukey's multiple comparison was performed. The per patient averages for LVL procedures, cryopreserved bags, staff hours, and costs in apheresis and CTL services were decreased significantly in 2023 compared to both control periods. However, for monthly analyses, differences were significant between 2023 and 2021; but not between 2023 and 2022. No differences were seen between the two control periods. The changes in autologous HPC collection goals led to a significant decrease in LVL procedures and cryopreserved bags required per patient to meet collection goals, reducing costs and workload for apheresis and CTL.

Keywords: HPC; cryopreserved products; large volume leukapheresis; workload cost savings.

PubMed Disclaimer

References

    1. S. V. Rajkumar and S. Kumar, “Multiple Myeloma Current Treatment Algorithms,” Blood Cancer Journal 10 (2020): 94.
    1. B. Dhakal, N. Shah, A. Kansagra, et al., “ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma,” Transplantation and Cellular Therapy 28 (2022): 284–293.
    1. N. S. Majhail, S. H. Farnia, P. A. Carpenter, et al., “Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines From the American Society for Blood and Marrow Transplantation,” Biology of Blood and Marrow Transplantation 21, no. 11 (2015): 1863–1869.
    1. I. Pusic, S. Y. Jiang, S. Landua, et al., “Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation,” Biology of Blood and Marrow Transplantation 14 (2008): 1045–1056.
    1. M. Mohty, K. Hubel, N. Kroger, et al., “Autologous Haematopoietic Stem Cell Mobilisation in Multiple Myeloma and Lymphoma Patients: A Position Statement From the European Group for Blood and Marrow Transplantation,” Bone Marrow Transplantation 49 (2014): 865–872.

MeSH terms

LinkOut - more resources